Lilly agrees to buy POINT Biopharma for $1.4bn
Two lead programmes of POINT, PNT2002 and PNT2003, are currently at the late developmental stage.

Two lead programmes of POINT, PNT2002 and PNT2003, are currently at the late developmental stage.
The company’s algorithms put proteins through millions of years of simulated evolution to identify potential functional candidates.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
ADDF invest in BrainScope for Alzheimer’s prediction biomarker
Market cap rebound by top 20 biopharmaceutical companies in Q2 2023
EMA CHMP recommends approval for Moderna’s updated Covid-19 vaccine
Corporate sustainability needs ESG standards and tools